Table 2.
N included sources | % of general detainee populations with HCV antibody prevalence data | Pooled HCV antibody prevalence (95% CI) | Prison detainee population | Estimated number of HCV antibody positive prison detainees | |||
---|---|---|---|---|---|---|---|
Low | Mid | High | |||||
Sub-Saharan Africa | 4 | 8 | 16 (7, 26) | 785,00 | 55,000 | 125,500 | 204,000 |
Western Europe | 39 | 92 | 30 (26, 34) | 478,500 | 124,500 | 143,500 | 162,500 |
Eastern Europe | 6 | 16 | 22 (14, 31) | 1,199,000 | 168,000 | 263,500 | 371,500 |
Latin America | 12 | 68 | 14 (8, 19) | 1,161,000 | 93,000 | 162,500 | 220,500 |
Australasia | 9 | 78 | 35 (28, 43) | 37,500 | 10,500 | 13,000 | 16,000 |
North America | 14 | 100 | 29 (24, 34) | 2,306,00 | 553,500 | 668,500 | 784,000 |
South Asia | 4 | 56 | 8 (4, 11) | 827,000 | 33,000 | 66,000 | 91,000 |
Middle East and North Africa | 1 | 1 | 3 (1, 5) | 491,500 | 5,000 | 14,500 | 24,500 |
East and Southeast Asia | 2 | 8 | 25 (13, 38) | 2,552,000 | 332,000 | 638,000 | 970,000 |
Central Asia | 1 | 8 | 38 (32, 43) | 123,500 | 39,500 | 47,000 | 53,000 |
Pacific Islands | - | 0 | - | 8,500 | - | - | - |
Caribbean | - | 0 | - | 34,000 | - | - | - |
Extrapolated global | 92 | 45 | 26 (23, 29) | 10,004,000 | 1,423,000 | 2,154,500 | 2,910,000 |
Note: ‘Prison’ includes all institutions for adults charged with, awaiting trial or sentenced for a criminal offence. It does not include compulsory detoxification centres. All figures rounded to the nearest 500 people. Extrapolated global figure totalled from regional estimates prior to rounding. “-“ indicates there were no data on HCV prevalence located in this region. These regions were included in the extrapolated global estimate by applying the total estimated HCV prevalence to the prison detainee population for these regions. Data on detainee populations obtained from the World Prison Brief of the International Centre for Prison Studies (http://www.prisonstudies.org/).